Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes

Diabetes

Volumn 55, Issue 11, 2006, Pages 3099-3103

  Mastorikou, Maria ^a   Mackness, Mike ^a   Mackness, Bharti ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; GLYCEROPHOSPHOLIPID; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PALMITOYL ARACHIDONYL PHOSPHATIDYLCHOLINE; PHOSPHOLIPID;

ADULT; ARTICLE; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PRIORITY JOURNAL;

ADULT; ARYLDIALKYLPHOSPHATASE; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; GENE FREQUENCY; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; PHOSPHATIDYLCHOLINES; PHOSPHOLIPIDS; POLYMORPHISM, GENETIC; REFERENCE VALUES; SEQUENCE DELETION;

EID: 33845530202     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-0723     Document Type: Article

References (33)

1. Steinberg D, Witztum JL: Is the oxidative modifications hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date reflect the hypothesis? Circulation 105:2107-2111, 2002
2. Parthasarathy S, Santanam N, Auge N: Oxidised low-density lipoprotein: a two-faced Janus in coronary artery disease? Biochem Pharmacol 56:279-284, 1998
3. Barter PJ, Rye KA: High density lipoproteins and coronary heart disease. Atherosclerosis 121:1-12, 1996
4. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaeffer EJ, Schectman G, Wilt TJ, Wittes J, the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410-418, 1999
5. Mackness MI, Durrington PN, Mackness B: How HDL protects against the effects of lipid peroxidation. Curr Opin Lipidol 11:383-388, 2000
6. Mackness MI, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152-154, 1991
7. Mackness MI, Arrol S, Abbott CA, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104:129-135, 1993
8. Watson AD, Berliner JA, Hama SY, La Du BN, Fault KF, Fogelman AM, Navab M: Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest 96:2882-2891, 1995
9. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-287, 1998
10. Aviram M: Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today 5:381-386, 1999
11. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, Fogelman AM: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88:2039-2046, 1991
12. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M: Paraoxonase 1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. BBRC 318:680-683, 2004
13. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuashia B, Miller JE, Boulton AJM, Durrington PN: Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139:341-349, 1998
14. Mackness B, Durrington PN, Abuashia B, Boulton AJM, Mackness MI: Low paraoxonase activity in type II diabetes complicated by retinopathy. Clin Sci 98:355-363, 2000
15. Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW: Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives: influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 155:229-235, 2001
16. Sampson MJ, Braschi S, Willis G, Astley SB: Paraoxonase-1 (PON1) genotype and activity and in vivo oxidised, plasma low-density lipoprotein in type II diabetes. Clin Sci (Lond) 109:189-197, 2005
17. Tsuzura S, Ikeda Y, Suehiro T, Ota K, Osaki F, Arii K, Kumon Y, Hashimoto K: Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism 53:297-302, 2004
18. Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P: Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscl Thromb Vasc Biol 26:1545-2550, 2006
19. Taskinen MR: Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733-749, 2003
20. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du BN: Paraoxonase active site required for protection against LDL oxidation involves its free sulphydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase alloenzymes Q and R. Arterioscl Thromb Vasc Biol 10:1617-1624, 1998
21. World Health Organization: WHO Expert Committee on Diabetes Mellitus. Second Report. Geneva, World Health Org., 1980 (Tech. Rep. Ser., no. 646).
22. El-Saadani M, Esterbauer H, El-Sayed M, Goher M, Nassar AY, Jurgens G: A Spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 30:627-630, 1989
23. Durrington PN: Disorders of lipid and lipoprotein metabolism. Section 11.6 In Oxford Textbook of Medicine. Vol. 2, 3rd ed. Weatherall D, Ledingham JGG, Warrell DA, Eds. Oxford University Press, Oxford, U.K., 1994, p. 1399-1415
24. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M: Low paraoxonase activity predicts coronary events in the Caerphilly prospective Study. Circulation 107:2775-2779, 2003
25. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM, Wong H, Peters AL: Glycation impairs high-density lipoprotein function. Diabetologia 43:312-320, 2000
26. Kordonouri O, James RW, Bennetts JB, Chan A, Kao YL, Danne T, Silink M, Donaghue K: Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism 50:657-660, 2001
27. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423:57-60, 1998
28. Tames FJ, Mackness MI, Arrol S, Laing I, Durrington PN: Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis 93:237-244, 1992
29. Jennings PE, Jones AF, Florkouski CM, Lunec J, Barnett AH: Increased diene conjugates in diabetic subjects with microangiopathy. Diabet Med 4:452-456, 1987
30. Aviram M, Dornfold L, Rosenblat M, Volkova N, Kaplan M, Coleman R, Hayek T, Presser D, Fuhrman B: Pomegranate juice consumption reduces oxidative stress, atherogenic modification of LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 71:1062-1076, 2000
31. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du BN: Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants. Free Rad Biol Med 26:892-904, 1999
32. Baker PW, Rye KE, Gamble JR, Vadas MA, Barter PJ: Ability of reconstituted high-density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res 40:345-353, 1999
33. Clay MA, Pyle DH, Rye KA, Vadas MA, Gamble JR, Barter PJ: Time sequence of inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. Atherosclerosis 157:23-29, 2001